FDA advisers to weigh updated COVID vaccine targeting XFG subvariant
Summary
The FDA’s vaccine advisory committee will meet to decide if the COVID-19 vaccine should be updated to target the XFG subvariant for the 2026-2027 respiratory virus season. This is part of ongoing efforts to adapt vaccines to new versions of the virus.Key Facts
- The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet on Thursday.
- The meeting will focus on possibly updating COVID-19 vaccines to target the XFG subvariant.
- The decision is for the upcoming 2026-2027 season when respiratory viruses like COVID-19 are common.
- The XFG subvariant is a newer version of the COVID-19 virus.
- This update would help the vaccine better protect people against this specific subvariant.
- The committee advises the FDA but does not make the final decision.
- Vaccine updates are common to keep up with changes in viruses over time.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.